Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 20/20 | 0.82 |
| ▸ | PRKCG | P05129 | 14/20 | 0.82 |
| ▸ | PRKCB | P05771 | 14/20 | 0.82 |
| ▸ | PRKCA | P17252 | 14/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.82 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.82 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.82 |
| ▸ | IDH1 | O75874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774124 | 0.90 | PRKCA (1.00) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL4343044 | 0.90 | GSK3B (0.66) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL13204205 | 0.89 | GSK3B (0.65) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL5759641 | 0.88 | PRKCA (0.95) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL5803991 | 0.88 | GSK3B (0.83) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL5758194 | 0.86 | GSK3B (0.88) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL4337219 | 0.86 | GSK3B (0.60) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL5758391 | 0.85 | GSK3B (0.90) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL5790814 | 0.84 | PRKCA (0.86) | GSK3BPRKCGPRKCBPRKCAKCNH2 | |
| SCHEMBL5757630 | 0.82 | GSK3B (0.84) | GSK3BPRKCGPRKCBPRKCAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-7786135-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-08-31 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7781450-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-24 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-7705015-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2010-04-27 | — | — | US | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | ZHANG HAN-CHENG | 2009-07-16 | — | — | US | disclosed |
| US-7524858-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| EP-1900738-A2 | Substituted pyrroline kinase inhibitors | Janssen Pharmaceutica, N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1506192-B1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7125878-B2 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA (BE) | 2006-10-24 | — | — | US | disclosed |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-14 | — | — | US | disclosed |
| EP-1506192-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | JANSSEN PHARMAECUTICA, NV (BE) | 2004-01-08 | — | — | US | disclosed |
| WO-2003095452-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205762-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCG 66/4885PRKCB 22/4885 |
| US-20040006095-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCG 66/4885PRKCB 22/4885 |
| US-20090181982-A1 | SUBSTITUTED PYRROLINE KINASE INHIBITORS | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCG 66/4885PRKCB 22/4885 |
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885PRKCG 104/4885PRKCB 61/4885 |
| US-20060205763-A1 | Substituted pyrroline kinase inhibitors | PRKDC, PRKACA, MAP3K20 | GSK3B 1267/4885PRKCG 66/4885PRKCB 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.